Tenax Therapeutics Completes Enrollment for Phase 3 LEVO-CTS Trial

Tenax Therapeutics (NASDAQ:TENX), which develops pharmaceutical products for the critical care market, today reported that it has completed patient enrollment in a Phase 3 LEVO-CTS trial.
As quoted in the press release:

The Company will lock its database after 30-day follow-up from the final patient, and currently expects to report top-line results in January 2017 in conjunction with the study’s lead investigators at Duke Clinical Research Institute (DCRI).

CEO John Kelley has said the following:

Consistent clinical execution and increased trial visibility has significantly accelerated the enrollment rate during these past 12 months, and we believe the expanded number of patients ensures that we have the best possible chance for success.

Read the full press release here.